A. Treatment with LL-37 alone results in a dose-dependent increase in late cell death (Annexin V+/7-AAD+) in HNEpCs. B. The percentage of total HNEpCs and J774.2 cells that are viable (Annexin V-/7-AAD-) is significantly reduced with LL-37 treatment, and this is dose-dependently reversed with GM-0111. C. The percentage of cells undergoing early death (Annexin V+/7-AAD-) is significantly increased in HNEpCs treated with LL-37, and the effect is reversed with GM-0111. D. The percentage of HNEpCs and J774.2 in late cell death (Annexin V+/7-AAD+) is also significantly increased with LL-37 treatment and dose-dependently reversed with GM-0111. ****P ≤ 0.0001, ***P ≤ 0.001, **P ≤ 0.01, *P ≤ 0.05, ns (not significant) P > 0.05. The data represent the means ± SD (n = 4).